The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.
April 23rd 2024
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA
The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.
FDA Grants Priority Review to Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma
The FDA has granted priority review to a biologics license application for the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients aged 12 years and older and weighing at least 40 kg who have unresectable or metastatic melanoma.
UV1 Vaccine Plus Pembrolizumab Shows Strong Safety, Early Activity in Metastatic Melanoma
September 2nd 2021The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor in combination with pembrolizumab elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial.
Topical Remetinostat Demonstrates Efficacy, Tolerability in Basal Cell Carcinoma
September 1st 2021The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.
FDA and EMA Accept Tebentafusp Applications for Metastatic Uveal Melanoma
The FDA and the European Medicines Agency have accepted applications seeking the approval of tebentafusp for use in the treatment of adult patients with HLA-A*02:01–positive metastatic uveal melanoma.
Clinicopathologic and Genomic Testing Confirm Differences in Pediatric Melanocytic Tumors
August 24th 2021Distinct subgroups of pediatric melanocytic lesions, which were identified by an integrated clinicopathologic and genomic analysis, were found to have different clinical behaviors, suggesting that this combined diagnostic modality could inform individualized diagnoses and treatments for patients with these rare malignancies.
FDA Grants Priority Review to Adjuvant Pembrolizumab for Stage II High-Risk Melanoma
The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.
Future Management of Uveal Melanoma
The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.
Uveal Melanoma: Patient Candidacy for Tebentafusp
Drs Richard D. Carvajal and Marlana M. Orloff highlight variables that should be considered when assessing the appropriateness for treating patients with uveal melanoma with tebentafusp.
Tebentafusp for Uveal Melanoma: Cytokine Release Syndrome
Advice to help educate patients about symptoms and management of cytokine release syndrome following treatment with tebentafusp for uveal melanoma.
Tebentafusp for Uveal Melanoma: Adverse Events
What to know about treatment response and treatment-related adverse events with tebentafusp for uveal melanoma.
Tebentafusp for Uveal Melanoma: Assessing Treatment Response
Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression.
Tebentafusp Efficacy Data in Uveal Melanoma
Implications for treating uveal melanoma with tebentafusp based on responses demonstrated by the IMCgp100-102 and IMCgp100-202 clinical studies.
Tebentafusp for Uveal Melanoma
Drs Richard D. Carvajal and Marlana M. Orloff comment on tebentafusp’s mechanism of action (MOA) and explain what makes the therapy attractive for uveal melanoma.
Uveal Melanoma: Current Treatment Approaches
A brief explanation regarding the difference between uveal melanoma and skin melanoma and an overview of standard treatment approaches used to treat patients with uveal melanoma.
Frontline Bempegaldesleukin/Nivolumab Continues to Elicit Durable Responses in Metastatic Melanoma
The combination of bempegaldesleukin plus nivolumab continued to produce promising antitumor activity with favorable tolerability when used in the frontline treatment of patients with metastatic melanoma, according to findings from a phase 2 cohort of the phase 1/2 PIVOT-2 trial.